Cancer Research The Future of Cancer Research: Science and Patient Impact Translational Medicine Conference in Israel
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Heink, S.
Right arrow Articles by Krüger, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Heink, S.
Right arrow Articles by Krüger, E.
[Cancer Research 66, 649-652, January 15, 2006]
© 2006 American Association for Cancer Research

Priority Reports

Tumor Cell Lines Expressing the Proteasome Subunit Isoform LMP7E1 Exhibit Immunoproteasome Deficiency

Sylvia Heink, Benjamin Fricke, Daniela Ludwig, Peter-M. Kloetzel and Elke Krüger

Institute of Biochemistry, Charité-Universitätsmedizin Berlin, Berlin, Germany

Requests for reprints: Elke Krüger, Institut für Biochemie, Charité-Universitätsmedizin Berlin, CCM, Monbijoustrasse 2, 10117 Berlin, Germany. Phone: 49-30-450-528186; Fax: 49-30-450-528921; E-mail: elke.krueger{at}charite.de.

The immune system can recognize antigenic peptides derived from tumors by their presentation on MHC class I complexes to CTLs. Immunoproteasomes (i20S) can substantially enhance the MHC class I peptide repertoire, making down-regulation of i20S an important strategy of tumor cells in manipulating immune surveillance. Here, we report that human cancer cells express the nonfunctional immunosubunit-variant LMP7E1, in addition to, or instead of LMP7E2, in response to IFN-{gamma}. This preferential expression of LMP7E1 and the consequent down-regulation of LMP7E2 results in i20S deficiency. The molecular explanation for this phenomenon is the incapacity of LMP7E1 to interact efficiently with the proteasome maturation protein, which regularly recruits LMP7E2 into nascent i20S precursor complexes. In contrast to previous reports, i20S formation in these cancer cells cannot be restored by IFN-{gamma} treatment. However, expression of LMP7E2 in these cells restores the i20S-deficient phenotype. Thus, our data describe a novel mechanism that contributes to the process of oncogenesis. (Cancer Res 2006; 66(2):649-52)




This article has been cited by other articles:


Home page
 BloodHome page
J. Dannull, D.-T. Lesher, R. Holzknecht, W. Qi, G. Hanna, H. Seigler, D. S. Tyler, and S. K. Pruitt
Immunoproteasome down-modulation enhances the ability of dendritic cells to stimulate antitumor immunity
Blood, December 15, 2007; 110(13): 4341 - 4350.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2006 by the American Association for Cancer Research.